Table 1:
Clinical Trials Targeting SHH Pathways in Female Cancers
| Target | Drug | Cancer type | Dose | Route | Phase | Clinical trials gov. identifier | Patient recruiting status |
|---|---|---|---|---|---|---|---|
| SMO | Vismodegib | Breast cancer | 400 mg | Oral | II | NCT01757327 | Withdrawn |
| SMO | Sonidegib | Breast cancer | Unknown | Oral | I | NCT01576666 | Completed |
| SMO | Vismodegib | Breast cancer | 150 mg | Oral | I | NCT01071564 | Terminated |
| SMO | Vismodegib | Breast cancer | Unknown | Oral | Ib | NCT03878524 | Recruiting |
| SMO | Vismodegib | Breast cancer | 150 mg | Oral | II | NCT02694224 | Recruiting |
| SMO | Vismodegib | Breast, Ovarian, Cervical, Endometrial Cancer | Unknown | Oral | II | NCT02465060 | Recruiting |
| SMO | Vismodegib | Ovarian | 150 mg | Oral | II | NCT00959647 | Completed |
| SMO | Vismodegib | Ovarian | 150 mg | Oral | II | NCT00739661 | Completed |
| SMO | Sonidegib | Ovarian | 400, 600 and 800 mg | Oral | I | NCT01954355 | Completed |
| SMO | Itraconazole | Ovarian | Unknown | Unknown | III | NCT03458221 | Not yet recruiting |